Double-barreled CAR-T takes aim at hard-to-treat blood cancer
NCT ID NCT07416682
First seen Feb 20, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This early-phase study tests a new cell therapy that targets two markers (BCMA and CD70) on high-risk plasma cell cancers, including multiple myeloma. About 20 participants will receive the treatment to see if it is safe and how well it works. The goal is to control the disease, not cure it, as lifelong monitoring or additional treatment may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Fifth Medical Center of Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.